ECSP088970A - Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia - Google Patents

Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia

Info

Publication number
ECSP088970A
ECSP088970A EC2008008970A ECSP088970A ECSP088970A EC SP088970 A ECSP088970 A EC SP088970A EC 2008008970 A EC2008008970 A EC 2008008970A EC SP088970 A ECSP088970 A EC SP088970A EC SP088970 A ECSP088970 A EC SP088970A
Authority
EC
Ecuador
Prior art keywords
neurodegeneration
dementia
alzheimer
disease
treatment
Prior art date
Application number
EC2008008970A
Other languages
English (en)
Inventor
Didier Rotticci
Stefan Berg
Karin Kolmodin
Niklas Plobeck
Fernando Sehgelmeble
Joerg Holens
Katharina Hogdin
Maria Wirstam
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Publication of ECSP088970A publication Critical patent/ECSP088970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a compuestos nuevos que tienen la fórmula estructural I siguiente: [Fórmula Química debe de insertarse aquí. Favor de ver copia de papel] y a sus sales, composiciones y métodos de uso farmacéuticamente aceptables. Estos compuestos nuevos proporcionan un tratamiento o profilaxis de trastornos cognitivos, enfermedad de Alzheimer, neurodegeneración y demencia.
EC2008008970A 2006-06-14 2008-12-12 Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia ECSP088970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81353906P 2006-06-14 2006-06-14
US89698407P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
ECSP088970A true ECSP088970A (es) 2009-01-30

Family

ID=38831995

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008970A ECSP088970A (es) 2006-06-14 2008-12-12 Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia

Country Status (18)

Country Link
US (1) US20080214577A1 (es)
EP (1) EP2044072A1 (es)
JP (1) JP2009539976A (es)
KR (1) KR20090031563A (es)
AR (1) AR061372A1 (es)
AU (1) AU2007259433A1 (es)
BR (1) BRPI0712735A2 (es)
CA (1) CA2654405A1 (es)
CL (1) CL2007001731A1 (es)
CO (1) CO6140033A2 (es)
EC (1) ECSP088970A (es)
IL (1) IL195668A0 (es)
MX (1) MX2008015584A (es)
NO (1) NO20090755L (es)
RU (1) RU2008148900A (es)
TW (1) TW200815447A (es)
UY (1) UY30408A1 (es)
WO (1) WO2007145571A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
PE20070135A1 (es) * 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
PE20080155A1 (es) 2006-06-12 2008-03-10 Schering Corp Compuestos heterociclicos como inhibidores de aspartil-proteasa
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008063114A1 (en) * 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
CA2723222C (en) * 2008-04-22 2013-04-02 Schering Corporation Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
US9422277B2 (en) 2012-10-17 2016-08-23 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
EA033686B1 (ru) 2015-08-03 2019-11-15 Bristol Myers Squibb Co Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
US20200165225A1 (en) * 2017-06-28 2020-05-28 Nantbio, Inc. Bace1 inhibitors for treatment of alzheimer's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
RU2006144075A (ru) * 2004-06-16 2008-07-27 Вайет (Us) ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ
CA2593515A1 (en) * 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
AR053902A1 (es) * 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
ATE478070T1 (de) * 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
JP2009513670A (ja) * 2005-10-31 2009-04-02 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
TW200815449A (en) * 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
US20080051420A1 (en) * 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317

Also Published As

Publication number Publication date
KR20090031563A (ko) 2009-03-26
JP2009539976A (ja) 2009-11-19
BRPI0712735A2 (pt) 2012-10-02
AR061372A1 (es) 2008-08-20
WO2007145571A1 (en) 2007-12-21
TW200815447A (en) 2008-04-01
RU2008148900A (ru) 2010-07-20
AU2007259433A1 (en) 2007-12-21
NO20090755L (no) 2009-03-09
IL195668A0 (en) 2009-09-01
EP2044072A1 (en) 2009-04-08
MX2008015584A (es) 2009-01-09
CL2007001731A1 (es) 2008-01-25
UY30408A1 (es) 2008-01-31
WO2007145571A9 (en) 2008-12-11
CO6140033A2 (es) 2010-03-19
CA2654405A1 (en) 2007-12-21
US20080214577A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
ECSP088970A (es) Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
JO2892B1 (en) CYP inhibitors 17
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY30407A1 (es) Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones.
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
CR10479A (es) Modulares bencimidazolicos de vr1
CO6690805A2 (es) 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3
UY30986A1 (es) Derivados fluorinados de deferiprona
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents